Efficacy of an H1 antagonist, astemizole, for chronic allergic rhinitis.

Abstract

Astemizole, a new histamine H1 receptor antagonist, was tested in a double-blind cross-over comparison study with chlorpheniramine maleate, a very effective conventional H1 antagonist, in patients with chronic allergic rhinitis. Astemizole was found to be equally effective, yet there was a significant decrease in the side effects of sleepiness (P less than .01) and dry mouth (P less than .05). Astemizole has a completely different structure and binding curves from terfenadine. It is approved for clinical use in the United Kingdom, Canada, and many European countries.

• Authors: W R Wilson, J Moss, M Joseph, N Laird, M Glinsiki
• Journal: American journal of otolaryngology (Am J Otolaryngol) 1987 May-Jun Vol. 8 Issue 3 Pg. 157-60 ISSN: 0196-0709 [Print] United States
• PMID: 2887123 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Benzimidazoles
• Histamine H1 Antagonists
• Chlorpheniramine
• Astemizole

Topics

• Astemizole
• Benzimidazoles (therapeutic use)
• Chlorpheniramine (therapeutic use)
• Clinical Trials as Topic
• Double-Blind Method
• Histamine H1 Antagonists (therapeutic use)
• Humans
• Rhinitis, Allergic, Perennial (drug therapy)